CorMedix Inc. will announce Q3 2025 financial results on November 12, followed by a conference call.
Quiver AI Summary
CorMedix Inc. has announced that it will release its financial results for the third quarter of 2025 on November 12, 2025, before the market opens and will hold a conference call at 8:30 AM ET the same day. The company focuses on developing therapeutic products for life-threatening conditions, primarily commercializing DefenCath, which aims to prevent catheter-related bloodstream infections in hemodialysis patients. Following its acquisition of Melinta Therapeutics in August 2025, CorMedix is also marketing several anti-infective products, including MINOCIN and REZZAYO, with ongoing clinical studies for DefenCath in various patient populations. Topline results for a pivotal study of REZZAYO are anticipated by Q2 2026.
Potential Positives
- CorMedix is preparing to report its financial results, indicating transparency and ongoing communication with investors.
- The company is actively expanding its product portfolio through the acquisition of Melinta Therapeutics, which enhances its market presence and therapeutic offerings.
- CorMedix has ongoing clinical studies for its lead product, DefenCath, indicating a commitment to research and development aimed at improving patient outcomes.
- Topline results for the Phase III study of REZZAYO are expected in Q2 2026, showcasing the company's progress in advancing its drug pipeline.
Potential Negatives
- The company has not provided any details about its financial performance prior to the upcoming announcement, which may raise concerns about transparency or potential financial difficulties.
- The lack of immediate positive news or updates in the press release may lead investors to speculate about possible issues impacting the company's growth or product pipeline.
- The upcoming Phase III study results for REZZAYO are not expected until Q2 2026, potentially indicating a lengthy timeline before any significant progress or revenue generation from that product.
FAQ
When will CorMedix report its third-quarter financial results?
CorMedix will report its financial results for the third quarter on November 12, 2025, before the market opens.
What time is the CorMedix corporate update conference call?
The corporate update conference call will take place at 8:30 am Eastern Time on November 12, 2025.
How can I join the CorMedix conference call?
You can join the conference call by calling 1-844-676-2922 domestically or 1-412-634-6840 internationally.
What therapeutic products does CorMedix develop?
CorMedix develops therapeutic products for life-threatening conditions, including DefenCath, and various anti-infective medications acquired from Melinta Therapeutics.
What is the focus of CorMedix's ongoing clinical studies?
The ongoing clinical studies focus on DefenCath for Total Parenteral Nutrition and pediatric patient populations, as well as catheter lock solutions.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CRMD Insider Trading Activity
$CRMD insiders have traded $CRMD stock on the open market 7 times in the past 6 months. Of those trades, 1 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $CRMD stock by insiders over the last 6 months:
- ELIZABETH HURLBURT (Chief Operating Officer) has made 0 purchases and 2 sales selling 53,997 shares for an estimated $711,817.
- KAUFMAN BETH ZELNICK (Chief Legal Officer) has made 0 purchases and 2 sales selling 50,000 shares for an estimated $670,264.
- JOSEPH TODISCO (Chief Executive Officer) sold 50,000 shares for an estimated $650,000
- MYRON KAPLAN purchased 25,000 shares for an estimated $275,500
- ALAN W DUNTON sold 10,000 shares for an estimated $131,300
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CRMD Hedge Fund Activity
We have seen 122 institutional investors add shares of $CRMD stock to their portfolio, and 48 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ELLIOTT INVESTMENT MANAGEMENT L.P. removed 2,444,561 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $30,116,991
- MARSHALL WACE, LLP added 2,349,451 shares (+1019.2%) to their portfolio in Q2 2025, for an estimated $28,945,236
- CITADEL ADVISORS LLC added 1,608,245 shares (+1517.6%) to their portfolio in Q2 2025, for an estimated $19,813,578
- NUVEEN, LLC added 1,194,040 shares (+434.7%) to their portfolio in Q2 2025, for an estimated $14,710,572
- GHISALLO CAPITAL MANAGEMENT LLC added 750,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $9,240,000
- ALYESKA INVESTMENT GROUP, L.P. added 750,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $9,240,000
- ANSON FUNDS MANAGEMENT LP added 725,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $8,932,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CRMD Analyst Ratings
Wall Street analysts have issued reports on $CRMD in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 10/21/2025
- D. Boral Capital issued a "Buy" rating on 10/20/2025
- JMP Securities issued a "Market Outperform" rating on 09/09/2025
- HC Wainwright & Co. issued a "Buy" rating on 08/08/2025
- Needham issued a "Buy" rating on 06/24/2025
To track analyst ratings and price targets for $CRMD, check out Quiver Quantitative's $CRMD forecast page.
$CRMD Price Targets
Multiple analysts have issued price targets for $CRMD recently. We have seen 5 analysts offer price targets for $CRMD in the last 6 months, with a median target of $20.0.
Here are some recent targets:
- Leonid Timashev from RBC Capital set a target price of $22.0 on 10/21/2025
- Jason Kolbert from D. Boral Capital set a target price of $14.0 on 10/20/2025
- Jason N. Butler from JMP Securities set a target price of $22.0 on 09/09/2025
- Brandon Folkes from HC Wainwright & Co. set a target price of $17.0 on 08/08/2025
- Serge Belanger from Needham set a target price of $20.0 on 06/24/2025
Full Release
BERKELEY HEIGHTS, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the third quarter ended September 30, 2025, before the market opens on Wednesday, November 12, 2025, and will host a corporate update conference call at 8:30am Eastern Time.
|
Wednesday, November 12
th
@ 8:30am ET
|
|
| Domestic: | 1-844-676-2922 |
| International: | 1-412-634-6840 |
| Webcast: | Webcast Link |
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing
DefenCath
®
(taurolidine and heparin) for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter. Following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix is also commercializing a portfolio of anti-infective products, including
MINOCIN
®
(minocycline),
REZZAYO
®
(rezafungin),
VABOMERE
®
(meropenem and vaborbactam),
ORBACTIV
™ (oritavancin),
BAXDELA
®
(delafloxacin), and
KIMYRSA
®
(oritavancin), as well as
TOPROL-XL
®
(metoprolol succinate).
CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition and Pediatric patient populations and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. REZZAYO is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of IFD in adult patients undergoing allogeneic BMT. Topline results of the Phase III study for REZZAYO are expected in Q2 2026. For more information visit: www.cormedix.com or www.melinta.com .
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
[email protected]
(617) 430-7576
